Drug Trial Radar · NCT07104110
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Oct 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
Conditions
- Prostatic Neoplasms
Interventions
QLH12016Drug
oral AR PROTAC
abiraterone acetateDrug
oral CYP17 inhibitor
enzalutamideDrug
oral androgen receptor inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of subjects with adverse events/serious adverse events (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
- The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol (Phase Ib)Time frame: From first dose of study treatment until the end of Cycle 1.
- Recommended phase II dose (RP2D) (Phase Ib)Time frame: Throughout phase Ib (approximately 1 year)
- Objective Response Rate (ORR) (Phase II)Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year)
- Objective Response Rate (ORR) (Phase II)Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.